GGrantIndex
Sort

50,496 grants matching lung cancer

Chemical Tools for Studying Fucosylated Glycans

$470,643
Peng Wu · Scripps Research Institute, The · R01 · FY2016 · GM

Development of New Casein Kinase 1 Inhibitor for the Treatment of Brain Cancers

$470,637
Derek Ronald Duckett · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2018 · CA

The Oncogenic and Tumor Suppressor Functions of the Kras isoform 4A in vivo

$470,631
Allan Balmain · University Of California, San Francisco · R01 · FY2016 · CA

UCLA Clinical Scientist Training in Cancer Gene Medicine

$470,621
University Of California Los Angeles · K12 · FY2003 · CA

Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics

$470,621
Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2022 · CA

Healthcare Access Dimensions and Racial Disparities in Lung Cancer

$470,547
Ying Liu · Washington University · R01 · FY2024 · MD

Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival

$470,514
Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Rac guanine nucleotide exchange factors in lung cancer

$470,493
Marcelo Gabriel Kazanietz · University Of Pennsylvania · R01 · FY2022 · CA

Transcriptional regulation of breast cancer metastasis

$470,456
Zena Werb · University Of California, San Francisco · R01 · FY2009 · CA

R01- Mapping environmental contributions to rapid lung disease progression in cystic fibrosis

$470,453
Rhonda Szczesniak · Cincinnati Childrens Hosp Med Ctr · R01 · FY2021 · HL

Cancer Genetic Markers of Susceptibility

$470,422
Stephen J Chanock · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA

Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer

$470,406
Jeffrey Paul Mackeigan · Michigan State University · R01 · FY2018 · CA

Protein Kinase C Signaling Mechanisms in Cancer

$470,306
Alan P Fields · Mayo Clinic Jacksonville · R01 · FY2019 · CA

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

$470,246
Ruoning Wang · Research Inst Nationwide Children'S Hosp · R01 · FY2022 · CA

Modulation of asparagine bioavailability and stress response signaling to enhance T cell robustness and maximize immunotherapy

$470,246
Ruoning Wang · Research Inst Nationwide Children'S Hosp · R01 · FY2023 · CA

Utilizing Interaction to Identify Novel Genetic Factors for Nicotine Dependence

$470,202
Dana B Hancock · Research Triangle Institute · R01 · FY2015 · DA

Whole Mouse Cryo-Imaging

$470,128
David L Wilson · Bioinvision, Inc. · R42 · FY2009 · CA

Development of Medical Countermeasures to Ricin Poisoning

$470,101
Thor Jon Borgford · Twinstrand Therapeutics, Inc. · U01 · FY2008 · AI

Accelerated statistical image reconstruction methods for X-ray CT

$470,100
Jeffrey A Fessler · University Of Michigan At Ann Arbor · U01 · FY2015 · EB

Chronic Respiratory Effect and Control of Occupational Exposure of Wildland Firefighters to Smoke

$470,054
Olorunfemi Adetona · Ohio State University · R01 · FY2023 · OH

Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer

$470,010
Tamara Minko · Rutgers, The State Univ Of N.J. · R01 · FY2017 · CA

Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)

$470,000
Davendra Sohal · University Of Cincinnati · R01 · FY2020 · FD

Immunoglobulin-Driven Activation of the Complement Cascade is a Critical Determinant of PAH Initiation and Progression

$469,957
Kurt R Stenmark · University Of Colorado Denver · P01 · FY2021 · HL

Immunoglobulin-Driven Activation of the Complement Cascade is a Critical Determinant of PAH Initiation and Progression

$469,957
Kurt R Stenmark · University Of Colorado Denver · P01 · FY2023 · HL

Immunoglobulin-Driven Activation of the Complement Cascade is a Critical Determinant of PAH Initiation and Progression

$469,957
Kurt R Stenmark · University Of Colorado Denver · P01 · FY2022 · HL